Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 20:11:380.
doi: 10.3389/fpsyt.2020.00380. eCollection 2020.

Depression in the Elderly. Consensus Statement of the Spanish Psychogeriatric Association

Luis Agüera-Ortiz  1   2 , María Dolores Claver-Martín  3 , María Dolores Franco-Fernández  4 , Jorge López-Álvarez  1 , Manuel Martín-Carrasco  5 , María Isabel Ramos-García  6 , Manuel Sánchez-Pérez  7
Affiliations

Depression in the Elderly. Consensus Statement of the Spanish Psychogeriatric Association

Luis Agüera-Ortiz et al. Front Psychiatry. .

Abstract

Introduction: Present knowledge about depression in the elderly is still scarce and often controversial, despite its high frequency and impact. This article reports the results and most relevant conclusions of a Delphi-based consensus on geriatric depression promoted by the Spanish Psychogeriatric Association.

Methods: A 78-item questionnaire was developed by 7 highly specialized geriatric psychiatrists and was evaluated using the Modified Delphi technique in two rounds answered by 35 psychiatrists with an extensive expertise in geriatric depression. The topics and number of questions (in brackets) covered were: concepts, clinical aspects, and risk factors (12); screening and diagnosis (7); psychotic depression (17); depression and dementia (5); antidepressant drug treatment (18); non-pharmacological biological treatments (5); psychotherapeutic treatments (4); comorbidity and preventive aspects (6); professional training needed (4). In addition, the expert panel's opinion on the antidepressants of choice in 21 common comorbid conditions and on different strategies to approach treatment-resistant cases in terms of both efficacy and safety was assessed.

Results: After the two rounds of the Delphi process, consensus was reached for 59 (75.6%) of the 78 items. Detailed recommendations are included in the text. Considering pharmacological treatments, agomelatine was the most widely mentioned drug to be recommended in terms of safety in comorbid conditions. Desvenlafaxine, sertraline, and vortioxetine, were the most frequently recommended antidepressants in comorbid conditions in general. Combining parameters of efficacy and safety, experts recommended the following steps to address cases of treatment resistance: 1. Escalation to the maximum tolerated dose; 2. Change of antidepressant; 3. Combination with another antidepressant; 4. Potentiation with an antipsychotic or with lamotrigine; 5. Potentiation with lithium; 6. Potentiation with dopamine agonists or methylphenidate.

Discussion and conclusions: Consensus was reached for a high number of items as well as for the management of depression in the context of comorbid conditions and in resistant cases. In the current absence of sufficient evidence-based information, our results can be used to inform medical doctors about clinical recommendations that might reduce uncertainty in the diagnosis and treatment of elderly patients with depressive disorders.

Keywords: antidepressant drugs; clinical recommendations; comorbidity; consensus statement; depression; elderly; treatment-resistance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Phases of the Delphi study.
Figure 2
Figure 2
Global results: Degree of consensus.
Figure 3
Figure 3
Priority strategy for efficacy in treatment-resistant depression.
Figure 4
Figure 4
Priority strategy for safety in treatment-resistant depression.
See this image and copyright information in PMC

References

    1. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 21(9):655–79. 10.1016/j.euroneuro.2011.07.018 - DOI - PubMed
    1. Olivera J, Benabarre S, Lorente T, Rodriguez M, Pelegrin C, Calvo JM, et al. Prevalence of psychiatric symptoms and mental disorders detected in primary care in an elderly Spanish population. The PSICOTARD Study: preliminary findings. Int J Geriatr Psychiatry (2008) 23(9):915–21. 10.1002/gps.2004 - DOI - PubMed
    1. Global Burden of Disease Study C Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 386(9995):743–800. 10.1016/S0140-6736(15)60692-4 - DOI - PMC - PubMed
    1. Valiengo Lda C, Stella F, Forlenza OV. Mood disorders in the elderly: prevalence, functional impact, and management challenges. Neuropsychiatr Dis Treat (2016) 12:2105–14. 10.2147/NDT.S94643 - DOI - PMC - PubMed
    1. Sjoberg L, Karlsson B, Atti AR, Skoog I, Fratiglioni L, Wang HX. Prevalence of depression: Comparisons of different depression definitions in population-based samples of older adults. J Affect Disord (2017) 221:123–31. 10.1016/j.jad.2017.06.011 - DOI - PubMed

LinkOut - more resources